Infectious Disease Alert – December 1, 2017
December 1, 2017
View Issues
-
Mumps Vaccine — Third Dose During Outbreaks
Mumps immunity wanes over time, with a notable increase in risk of infection 13 or more years after completion of the currently recommended series of vaccines. During an outbreak of mumps, receipt of an extra (third, by American schedules) vaccine significantly reduces the risk of becoming sick with mumps.
-
Lyme Disease in the United States — Good News, Bad News
The incidence of Lyme disease appears to have stabilized in states with known high incidences of the infection, but there is evidence of geographic expansion into neighboring states.
-
Statin Use Is Associated With a Lower Risk of Community-acquired Staphylococcus aureus Bacteremia
A population-based case-control study from Denmark found the use of statins was associated with a decreased risk for community-associated Staphylococcus aureus bacteremia, with the greatest benefit from higher doses.
-
Meropenem-vaborbactam
Meropenem-vaborbactam (Vabomere) is the latest β-lactam/β-lactamase inhibitor (BLI), approved by the FDA in August 2017 for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults older than 18 years of age.
-
Stewardship, Science, and Spirituality
Awareness of a patient’s and family’s belief system might help physicians appropriately frame explanations about the importance of antimicrobial stewardship.
-
Etiology of Acute Liver Failure and Next-generation Sequencing
Metagenomic next-generation sequencing was applied to examine serum from 204 adult patients with acute liver failure (ALF). Researchers identified a potential viral etiology in eight of the 187 patients with ALF of indeterminate etiology. Potential pathogens identified in these included HSV-1, HBV, parvovirus B19, CMV, and HHV-7.
-
Secnidazole Oral Granules (Solosec)
The FDA has approved the first oral single-dose treatment for bacterial vaginosis in adult women.